Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
China Medical University, China
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07034391CT.gov A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status | — | Recruiting | — | — | — |
NCT03958565CT.gov Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. | — | Recruiting | — | — | — |
NCT03669523CT.gov Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) | — | Completed | — | — | — |
NCT02129699CT.gov Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy | — | Terminated | — | — | — |
NCT01951586CT.gov Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00896454CT.gov Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Denosumab (this asset) | China Medical University, China | P3 | CCC · 52 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Denosumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Carcinoma In The Bone | — | P4 | BBB · 76 |
| Breast Carcinoma | — | P3 | BB · 66 |
| Breast Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Denosumab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/denosumab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →